Overview

An Open-label Extension to Evaluate the Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease

Status:
Completed

Trial end date:
2006-07-01

Target enrollment:

Participant gender:

Summary

The goal of this research study is to evaluate, in the open-label extension phase, the safety and efficacy of the rivastigmine transdermal patch in patients with probable Alzheimer's Disease

Phase:

Phase 3

Details

Lead Sponsor:

Novartis

Treatments:

Rivastigmine